Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. Issue 6 (11th June 2016)

• Record Type: Journal Article
• Authors: Ouyang, Juan; Goswami, Maitrayee; Peng, Jie; Zuo, Zhuang; Daver, Naval; Borthakur, Gautam; Tang, Guilin; Medeiros, L. Jeffrey; Jorgensen, Jeffrey L.; Ravandi, Farhad; Wang, Sa A.
• Is Part Of: American journal of clinical pathology. Volume 145:Issue 6(2016)
• Page Start: 769
• Page End: 777
• Publication Date: 2016-06-11
• Subjects: Flow cytometry -- qRT-PCR -- Core binding factor -- Acute myeloid leukemia -- Minimal residual disease; Diagnosis, Laboratory -- Periodicals; Pathology -- Periodicals; 616.07
• DOI: 10.1093/ajcp/aqw038
• Languages: English
• ISSNs: 0002-9173

Abstract

Abstract: Objectives: To examine the value of minimal residual disease (MRD) by multiparameter flow cytometry (MFC) in core binding factor (CBF) acute myeloid leukemia (AML). Methods: We studied 42 patients with t(8;21)(q22;q22)/ RUNX1-RUNX1T1 and 51 with inv(16)(p13.1q22)/ CBFB-MYH11 . Tandem MRD analyses by MFC and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were performed in 281 bone marrow (BM) samples. Results: Grouping qRT-PCR levels as ≤0.01, 0.01 to 0.1, 0.1 to 1, 1 to 10, and >10%, and reporting MFC (sensitivity, 0.1%-0.01%) as positive or negative, κ coefficient test showed no agreement between qRT-PCR and MFC in BM samples obtained postinduction (n = 44, κ = 0.041), and only weak agreement during consolidation (n = 108, κ = 0.083), maintenance/follow-up (n = 107, κ = 0.164), and salvage chemotherapy (n = 24, 0.376). In the post induction BM samples, while qRT-PCR <0.1% was associated with lower and ≥10% with higher AML relapse risk ( P = .035), qRT-PCR between 0.1% to 1% and 1% to 10% failed to predict relapse. In the latter group with intermediate qRT-PCR results, MFC provided prognostic value for relapse ( P = 0.006). Conclusions: MFC and qRT-PCR are complementary tests in monitoring CBF AML MRD.